Abbvie Inc
NYSE:ABBV
Abbvie Inc
Cash Equivalents
Abbvie Inc
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$12.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
3%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$8.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
15%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$10.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$11.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
33%
|
CAGR 10-Years
35%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$16.2B
|
CAGR 3-Years
95%
|
CAGR 5-Years
62%
|
CAGR 10-Years
41%
|
|
Seagen Inc
NASDAQ:SGEN
|
Cash Equivalents
$428.6m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
30%
|
CAGR 10-Years
14%
|
See Also
What is Abbvie Inc's Cash Equivalents?
Cash Equivalents
12.8B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Cash Equivalents amounts to 12.8B USD.
What is Abbvie Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
3%
Over the last year, the Cash Equivalents growth was 39%. The average annual Cash Equivalents growth rates for Abbvie Inc have been 15% over the past three years , 12% over the past five years , and 3% over the past ten years .